MedTrace Logo

Single Dose PK of IV Tedizolid Phosphate in Morbidly Obese and Non-Obese Adults

NCT02342418 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2017-03-15

Study results available
· View outcomes & findings →

Summary

This is an open label, single-dose, pharmacokinetic study in 9 obese and 9 age-, sex-, ideal body weight- matched non-obese subjects. Qualifying subjects who have completed an informed consent will receive a single intravenous dose of tedizolid with the collection of 11 blood samples over 72 hours post dose.

Conditions

Interventions

DRUG

Tedizolid phosphate

Each group will receive a single dose of tedizolid phosphate 200 mg through a peripheral intravenous catheter.

Sponsors & Collaborators

Principal Investigators

  • Manjunath Pai, PharmD · University of Michigan

Study Design

Allocation
NON_RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2015-09-30
Completion
2015-12-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02342418 on ClinicalTrials.gov